AstraZeneca To Fund Rs 250 crore on expansion of its GCC in India

AstraZeneca India Private Limited (AZIPL), the British-Swedish drugmaker's global capabilities center (GCC), has announced a Rs 250 crore ($30 million) investment to expand its Global Innovation and Technology center (GITC) in Chennai.

The expansion includes the addition of nearly 1,300 new jobs aimed at boosting innovation, improving efficiency, and streamlining processes throughout the company's global footprint. The facility now occupies 334,000 square feet of office space at Ramanujan IT City, with plans to expand by about 180,000 square feet over the next six months, making it AstraZeneca's largest global capabilities center.

The expanded GITC will use technologies including enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics to influence healthcare outcomes.

Since its inception, the GITC in Chennai has progressed from providing traditional information technology support services to becoming an engine of AstraZeneca's digital journey, driving productivity, simplification, technology delivery, and innovation across the company's global operations, thereby facilitating the delivery of life-changing medicines to patients worldwide.

Including GITC, AstraZeneca employs over 4000 individuals in the country and is constantly developing competent, diverse, and future-ready talent. AstraZeneca promotes and distributes its revolutionary portfolio in specialty disease areas such as oncology, cardio-vascular, respiratory, and rare disease, in addition to serving as a hub for technology and research and development.